CoChat

Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets

Open access
Aguiar, Pedro Nazareth, De Mello, Ramon Andrade, Barreto, Carme lia Maria Noia, Perry, Luke Alastair, Penny-Dimri, Jahan, Tadokoro, Hakaru, Lopes, Gilbertode Lima · 2017 · ESMO Open
Cited by 44

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Lung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells. These agents are available for the treatment of non-small cell lung cancer (NSCLC) after failure of platinum-based therapy. One recent study has demonstrated that ICI monotherapy was superior to platinum-based chemotherapy for first-line treatment. Nevertheless, this benefit was only for a minority of the population (30%) whose tumour programmed death receptor ligand-1 (PD-L1) expression was above 50%. Therefore, several strategies are under investigation. One option for patients with PD-L1 expression lower than 50% may be the combination of ICI with platinum-based chemotherapy or with ICIs against different targets. However, all of these combinations are at an early stage of investigation and may be very expensive or toxic, producing several harmful adverse events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/esmoopen-2017-000200

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 44

Metadata

Authors
Aguiar, P. N., De Mello, R. A., Barreto, C. L. M. N., Perry, L. A., Penny-Dimri, J., Tadokoro, H., & Lopes, G. L.
Venue
ESMO Open
Publisher
Elsevier BV
Published
2017
Volume
2
Issue
3
Pages
e000200
ISSN
2059-7029 (ISSN-L)
OpenAlex
W2740806763
Cited by
44
References
9
FWCI
2.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. https://app.cochat.ai/papers/10.1136/esmoopen-2017-000200
The paper
Aguiar, P. N., De Mello, R. A., Barreto, C. L. M. N., Perry, L. A., Penny-Dimri, J., Tadokoro, H., & Lopes, G. L. (2017). Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. ESMO Open. https://doi.org/10.1136/esmoopen-2017-000200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.